Pediatric drug-sensitive tuberculosis treatment regimen profiles and treatment outcomes in mainland China, 2017–2022: a multi-center study
Xinxin Zeng, Hao Xu, Aole Li, Juanjuan Liu, Yuhang Wu, Xingyu Dong, Xin Yu, Hongmei Xu, Ping Liu, Juan Ma, Qingshan Cai, Haiyan Li, Man Tian, Qing Fang, Guangxu Yang, Fei Wang, Bin Chen, Lisu Huang · 2025
Read Pediatric drug-sensitive tuberculosis treatment regimen profiles and treatment outcomes in mainland China, 2017–2022: a multi-center study by Xinxin Zeng, Hao Xu, Aole Li, Juanjuan Liu, Yuhang Wu, Xingyu Dong, Xin Yu, Hongmei Xu, Ping Liu, Juan Ma, Qingshan Cai, Haiyan Li, Man Tian, Qing Fang, Guangxu Yang, Fei Wang, Bin Chen, Lisu Huang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12849109.txt.
Description
Xinxin Zeng and co-authors chart child tuberculosis care in mainland China in a 2025 study. World guides set how drug-sensitive child TB should be treated, yet real practice in China was little mapped. Records came from ten referral hospitals across four regions, spanning 2017 to 2022.
Near six hundred children under fifteen were enrolled. Three in four had lung TB alone, and the rest had spread beyond the lungs. About two-thirds got the standard core drug set. Over a quarter got regimens with second-line drugs, which are held back for hard cases. Cure results, harms, and course length were logged per regimen. The map shows where practice drifts from guides.
Catalog record
| CREATOR | Xinxin Zeng, Hao Xu, Aole Li, Juanjuan Liu, Yuhang Wu, Xingyu Dong, Xin Yu, Hongmei Xu, Ping Liu, Juan Ma, Qingshan Cai, Haiyan Li, Man Tian, Qing Fang, Guangxu Yang, Fei Wang, Bin Chen, Lisu Huang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |